A 52-year-old man with multiple myeloma is started on high-dose melphalan followed by autologous stem cell transplantation. Which is the most common acute hematological toxicity expected within the first 2–3 weeks post-transplantation?

Explanation

## Melphalan and Post-Transplant Hematological Toxicity ### Mechanism of Myelosuppression **Key Point:** Melphalan is a nitrogen mustard alkylating agent that causes dose-dependent, cumulative myelosuppression. In high-dose myeloablative regimens (>100 mg/m²), it causes profound pancytopenia. **High-Yield:** Severe thrombocytopenia is the most common and dose-limiting hematological toxicity after high-dose melphalan, typically occurring 7–14 days post-infusion and resolving by day 21–28 with stem cell engraftment. ### Timeline of Myelosuppression After High-Dose Melphalan ```mermaid flowchart TD A[High-dose melphalan infusion]:::action --> B[Days 0-3: Drug metabolism & DNA damage]:::outcome B --> C[Days 4-7: Bone marrow aplasia begins]:::outcome C --> D[Days 7-14: Nadir of all cell lines]:::urgent D --> E{Stem cell engraftment?}:::decision E -->|Yes| F[Hematological recovery days 14-28]:::action E -->|No| G[Prolonged pancytopenia]:::urgent D --> H[Thrombocytopenia most severe]:::urgent D --> I[Neutropenia second]:::urgent D --> J[Anemia least severe initially]:::outcome ``` ### Why Thrombocytopenia is Most Common 1. **Dose-dependent effect:** Melphalan causes direct, cumulative DNA damage to hematopoietic stem cells 2. **Megakaryocyte sensitivity:** Megakaryocytes are among the most radiosensitive bone marrow elements 3. **Longer recovery:** Platelet recovery lags behind neutrophil recovery by 3–7 days 4. **Clinical consequence:** Platelet transfusion requirement is the most frequent supportive care need ### Hematological Recovery Hierarchy (Post-Stem Cell Engraftment) | Cell Line | Nadir (Days) | Recovery (Days) | Transfusion Need | |-----------|--------------|-----------------|------------------| | **Platelets** | 7–14 | 14–28 | **Very high** | | Neutrophils | 7–14 | 10–21 | High (G-CSF used) | | RBC | 10–21 | 21–35 | Moderate | **Clinical Pearl:** Platelet transfusion thresholds in post-transplant patients are typically set at <10,000–20,000/µL (vs. <5,000/µL in stable patients) due to increased bleeding risk from fever, mucositis, and coagulopathy. **Mnemonic:** **MELT** — **M**elphalan causes **E**arly **L**oss of **T**hrombocytes (and other cells, but platelets are most clinically significant). ### Distinction from Other Toxicities | Toxicity | Timing | Mechanism | Frequency | |----------|--------|-----------|----------| | **Thrombocytopenia** | Days 7–14 (nadir) | Direct marrow suppression | **Most common** | | Hemolytic anemia | Days 3–7 (if occurs) | Immune-mediated (rare post-melphalan) | Rare | | DIC | Days 5–14 | Secondary to infection/sepsis | Uncommon | | Autoimmune cytopenias | Weeks 2–4 | GVHD or immune dysregulation | Rare | **Warning:** Do not confuse **melphalan-induced thrombocytopenia** (predictable, dose-dependent) with **immune thrombocytopenia** (unpredictable, immune-mediated). The former is expected; the latter is a complication.